Efficacy and safety of taxanes combined with chemotherapy drugs in advanced triple negative breast cancer: a meta-analysis of 26 randomized controlled trials

HIGHLIGHTS

• who: Qionglian Huang from the University, China have published the article: Efficacy and safety of taxanes combined with chemotherapy drugs in advanced triple negative breast cancer: A meta-analysis of 26 randomized controlled trials, in the Journal: (JOURNAL) of February/20,/2022
• what: PFS, the most common primary endpoint in cancer trials, is defined as the time from the date of initial treatment to the date of the first objective documentation of disease progression or the date of the last follow-up for patients who are still alive without disease progression or death without disease . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.